Next Microbiome Session – Wednesday, January 17th

Presenter: Alissa Cait
Presentation: Understanding the effect of the microbiome and microbial metabolites on early life immune-development with long term consequences for asthma.
Time: 12:00 -1:00 PM
Where: Djavad Mowafaghian Centre for Brain Health [DMCBH], 3402 A&B

Address: 2215 Wesbrook Mall, Vancouver, BC V6T 2B5
Directions: Enter through main doors of DMCBH and take elevator up to 3rd floor. Make a right off the elevator and walk through the glass doors. You will be able to see us.

What: A monthly Microbiome seminar series including speakers and journal club

Why: The goal of this seminar series is to provide a focal point for trainees, PIs and other interested individuals to discuss and learn about the microbiome. While an overarching theme is the microbiome and its relation to brain health, a much broader range of topics on the microbiome will be covered as skills, techniques and study design are transferable across disciplines, body sites and ecosystems.

Who: All are invited; of relevant to anyone interested in the microbiome. This series is dependent on participation - please consider volunteering for journal club - talk to your PI about presenting.

Contact us!

If anyone is available to present at the upcoming dates, we do have openings in 2018. Please let me know if you would like to present.

Join email blasts about upcoming sessions: Please contact Michelle Eisner at meisner@brain.ubc.ca

Faculty: Dr. Helen Tremlett.
Professor and Canada Research Chair in Neuroepidemiology and Multiple Sclerosis
Faculty of Medicine (Neurology). Web-site: http://epims.med.ubc.ca/

Michelle Eisner | Program Coordinator
UBC MS Connect Education Program | University of British Columbia
S195-2211 Wesbrook Mall | Vancouver, British Columbia, V6T 2B5
Phone: 604-827-3111 | Email: meisner@brain.ubc.ca

Funding for the UBC MS Connect Education Program has been generously supported by unrestricted educational grants by Sanofi Genzyme, Novartis, Roche, EMD Serono, Biogen Idec, Teva Canada and The Christopher Foundation.